European Committee for Treatment & Research in Multiple Sclerosis

Startseite
Schweiz
Basel
European Committee for Treatment & Research in Multiple Sclerosis

ECTRIMS is dedicated to the understanding and treatment of multiple sclerosis (MS). Learn more below

Through our Patient Community Hub, we connect people living with MS and related conditions with trusted, up-to-date scientific information. The Patient Community Hub empowers those affected by MS, NMOSD, and MOGAD. By bringing patients, families, and experts together, we ensure no one faces these challenges alone, providing a consistent resource for connection and education.

02/09/2026

Living with multiple sclerosis means navigating a lot of information — and you don't have to do it alone.

𝐒𝐢𝐠𝐧 𝐮𝐩 𝐭𝐨 𝐨𝐮𝐫 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐂𝐨𝐦𝐦𝐮𝐧𝐢𝐭𝐲 𝐧𝐞𝐰𝐬𝐥𝐞𝐭𝐭𝐞𝐫 𝐭𝐨 𝐫𝐞𝐜𝐞𝐢𝐯𝐞:

· Clear updates on the latest MS research

· Information about upcoming Patient Community Day events

· Practical insights you can use in everyday life

· News from MS organisations and regional partners around the world

Stay informed. Stay connected. Be part of a global MS community.

𝐒𝐮𝐛𝐬𝐜𝐫𝐢𝐛𝐞 𝐡𝐞𝐫𝐞: https://bit.ly/4jv47Bv

01/09/2026

🌍 60 Supporting Partners — and counting.

Patient Community Day 2026 has officially reached 60 Supporting Partners, with organisations from all six continents taking part this year.

Advocacy groups, healthcare institutions, research centres and professional societies are working alongside ECTRIMS to share trusted information and connect MS, NMOSD and MOGAD communities with the latest developments in research.

Bringing organisations from around the world together helps bridge the gap between scientific knowledge and the communities it matters to most.

We’re grateful to every Supporting Partner for their commitment and for being part of this global effort.

👉 𝐉𝐨𝐢𝐧 𝐮𝐬 𝐟𝐨𝐫 𝐄𝐂𝐓𝐑𝐈𝐌𝐒 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐂𝐨𝐦𝐦𝐮𝐧𝐢𝐭𝐲 𝐃𝐚𝐲 𝐨𝐧 23 𝐎𝐜𝐭𝐨𝐛𝐞𝐫 2026, 𝐢𝐧 𝐓𝐨𝐫𝐨𝐧𝐭𝐨 𝐨𝐫 𝐨𝐧𝐥𝐢𝐧𝐞: https://bit.ly/44elQGb

European Committee for Treatment & Research in Multiple Sclerosis

30/08/2026

What happens between appointments matters.

The Spanish NMOSD & MOGAD Association ( Asociación Española Nmosd: NMO y MOGAD ) is raising awareness of the Registro de Síntomas NMO y MOGAD App, a digital tool designed to help people living with NMOSD and MOGAD keep track of their symptoms between appointments.

Six months or even a year can pass between visits with a neurologist. During that time, symptoms can change from day to day, making it difficult to remember every detail when the next appointment finally arrives.

𝐖𝐢𝐭𝐡 𝐭𝐡𝐞 𝐚𝐩𝐩, 𝐩𝐞𝐨𝐩𝐥𝐞 𝐜𝐚𝐧:
🔹 Track symptoms day by day
🔹 Create reports to share with their neurologist
🔹 Choose to contribute anonymised data to NMOSD and MOGAD research

For a rare disease community spread across Spain, the app is more than a tracking tool. It can help turn everyday experiences into meaningful information.

👉 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐬𝐭𝐨𝐫𝐲 𝐚𝐧𝐝 𝐥𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐞 𝐚𝐩𝐩: https://bit.ly/3Uavbh3

30/08/2026

🎧 New Podcast Episode: Predicting MS — Can Data Bring Us Closer to Personalised Care?

Two people of the same age, with a similar duration of MS and apparently similar MRI scans, can experience completely different disease trajectories.

So how do we predict what comes next for an individual?

In this episode of the ECTRIMS Podcast, Dr. Will Brown from the Cambridge Clinical Multiple Sclerosis Research at University of Cambridge and Dr. Carmen Tur from CEMCAT join Brett Drummond from MStranslate to explore how large real-world datasets and predictive modelling are changing what researchers can ask about multiple sclerosis.

𝐓𝐡𝐞𝐲 𝐝𝐢𝐬𝐜𝐮𝐬𝐬:

🔹 Why the biological and clinical heterogeneity of MS makes prediction so difficult

🔹 How large real-world datasets are changing what researchers can investigate

🔹 The challenges of missing data, non-random treatment allocation and defining meaningful clinical outcomes

🔹 How AI and machine learning could contribute — and why a good model still begins with the right clinical question

🔹 How underrepresentation in datasets could deepen existing health inequalities

🔹 What must happen before predictive tools can meaningfully influence treatment decisions in clinical practice

The potential is significant. But as Will and Carmen explain, accurately predicting an outcome is only the beginning — the ultimate test is whether using that prediction actually improves care.

🎧 𝐋𝐢𝐬𝐭𝐞𝐧 𝐧𝐨𝐰 — 𝐥𝐢𝐧𝐤𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐜𝐨𝐦𝐦𝐞𝐧𝐭𝐬.

European Committee for Treatment & Research in Multiple Sclerosis

28/08/2026

🌍 Finding the right neurologist or specialist in Poland shouldn't be a guessing game, especially after an MS diagnosis.

That's the gap PTSR (Polskie Towarzystwo Stwardnienia Rozsianego) set out to close with Mapa SM, an interactive directory helping people locate hospitals, clinics, and specialists across Poland who treat MS, NMOSD, and MOGAD, from neurologists to physiotherapists. Search by region or city,, and find relevant care within 100km.

It's just one part of PTSR's wider work as a nationwide organisation supporting people with MS to access treatment, rehabilitation, and the resources they need to work, build families, and thrive.

👉 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐌𝐚𝐩𝐚 𝐒𝐌: https://bit.ly/4wwc3Yk

As part of our Global Supporting Partners Series of Patient Community Day, we're introducing you to the organisations, initiatives, and people helping to strengthen the MS, NMOSD and MOGAD community worldwide.

26/08/2026

Advances in remyelination and myelin repair are opening new possibilities in the future of MS treatment.

At Patient Community Day 2026, leading experts will explore the latest breakthroughs in this area – helping to explain what these developments could mean for people living with MS, now and in the years ahead.

📅 23 October 2026
🕒 15:00–18:00 EDT, plus a bonus hour of Q&A for online participants
🌍 Online + Toronto, Canada
🌐 Live translations available in 50+ languages

👉 𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐧𝐨𝐰: https://bit.ly/44elQGb

European Committee for Treatment & Research in Multiple Sclerosis

24/08/2026

This past July, The Nerve of My Multiple Sclerosis CIC marked four years since it was founded.

In that time, it has grown from one person wanting to change how these conditions are talked about into an international community supporting Black heritage communities affected by MS and other neuroimmune conditions, with connections across the UK, Ghana and Nigeria.

To mark its fourth anniversary, this Patient Community Day Supporting Partner is launching the 1st Black Neuroimmune Diseases Patient Day 2026 – to be held on 𝐒𝐚𝐭𝐮𝐫𝐝𝐚𝐲 12 𝐒𝐞𝐩𝐭𝐞𝐦𝐛𝐞𝐫 2026 in the UK.

This community-focused event is designed to support people of Black heritage, their families and carers, living with:

• Multiple sclerosis (MS)
• Neuromyelitis optica spectrum disorder (NMOSD)
• MOG antibody-associated disease (MOGAD)
• Clinically isolated syndrome (CIS)
• Stiff person syndrome (SPS)

𝐅𝐢𝐧𝐝 𝐨𝐮𝐭 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐞 𝐝𝐚𝐲 𝐚𝐧𝐝 𝐡𝐨𝐰 𝐭𝐨 𝐭𝐚𝐤𝐞 𝐩𝐚𝐫𝐭 𝐛𝐞𝐥𝐨𝐰.

𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐞 𝐝𝐚𝐲: https://bit.ly/3SHcb9m

𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐞𝐯𝐞𝐧𝐭: https://bit.ly/4xHJury

As part of our Global Supporting Partners Series of Patient Community Day, we're introducing you to the organisations, initiatives, and people helping to strengthen the MS, NMOSD and MOGAD community worldwide.

22/08/2026

🌍 Looking for a resource that makes MS research easy to understand? Meet RealTalk MS.

Hosted by Jon Strum, the podcast sits down with scientists, policymakers, and patients each week to unpack what a new trial result or a policy vote actually means for people living with MS.

Since launching, RealTalk MS has covered topics including FDA submissions, newly approved therapies, congressional funding decisions, and emerging research linking menopause to MS progression, often featuring the researchers behind the findings themselves.

👉 𝐋𝐢𝐬𝐭𝐞𝐧 𝐭𝐨 𝐭𝐡𝐞 𝐥𝐚𝐭𝐞𝐬𝐭 𝐞𝐩𝐢𝐬𝐨𝐝𝐞: https://bit.ly/3SvhTLn

As part of our Global Supporting Partners Series of Patient Community Day, we're introducing you to the organisations, initiatives, and people helping to strengthen the MS, NMOSD and MOGAD community worldwide.

15/08/2026

For the past 10 years, the MS Research Flagship at the Menzies Institute for Medical Research in Tasmania, Australia, has brought together researchers, clinicians and people living with MS.

At the heart of its work is a simple principle: “Nothing about us without us.”

Since 2016, they have worked side by side to better understand MS and help shape research around the priorities of the MS community.

Over the past decade, the Flagship has advanced research into the causes of MS, established Australia’s first dedicated MS biobank, pioneered stem cell research and led clinical trials exploring new approaches to brain repair.

As the MS Research Flagship marks its 10-year anniversary, read more about the research, the people involved and the work being done in Tasmania and beyond.

🔗 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐛𝐥𝐨𝐠: https://bit.ly/4qaURpF

14/08/2026

💬 “One of the most powerful things we can do is learn from each other.”

Elisabeth Kasilingam, CEO of the European Multiple Sclerosis Platform (EMSP), understands the importance of bringing people together—not only to hear from experts, but to share experiences, perspectives and challenges.

Patient Community Day creates a unique space where people affected by MS, NMOSD and MOGAD can connect with a global community while gaining trusted insights from the world's leading researchers and clinicians.

🌍 Connect with people from around the world
🎓 Learn about the latest scientific advances
❓ Hear answers to real questions from the community
🗣️ Follow the event in 50+ languages

Join thousands of people worldwide for Patient Community Day 2026 on 23 October.

🔗 𝐒𝐢𝐠𝐧 𝐮𝐩 𝐧𝐨𝐰: https://bit.ly/4w5pdvp

European Committee for Treatment & Research in Multiple Sclerosis

Adresse

Reinacherstrasse 131
Basel
4053

Telefon

+41616867777

Webseite

http://www.ectrims.eu/, https://www.ectrimspatientcommunity.eu/, https://www.linkedin.com/company/ectrims/, https://x.co

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von European Committee for Treatment & Research in Multiple Sclerosis erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.